Oral semaglutide is the same molecule as the injection, pressed into a daily tablet with an absorption enhancer called SNAC. Current Rybelsus and Ozempic tablet labeling estimates absolute bioavailability at 0.4% to 1% for Rybelsus and 1% to 2% for Ozempic tablets; current Wegovy labeling estimates 1% to 2% for Wegovy tablets. All three labels direct fasting administration with up to 4 ounces of water and a 30-minute wait before food, other drinks, or other oral medicines. Three branded oral semaglutide products are listed in current U.S. labeling: Rybelsus tablets (3 mg, 7 mg, and 14 mg), Ozempic tablets (1.5 mg, 4 mg, and 9 mg), and Wegovy tablets (25 mg after dose escalation).
If your question is the broader trade-off between swallowing and injecting, GLP-1 pills versus injections covers it. This page is about the oral formulation itself.
What SNAC does, and why a peptide needs it
Semaglutide is a 31-amino-acid analogue of GLP-1. Peptides that size are broken down by stomach acid and digestive enzymes long before they reach the bloodstream, which is why nearly every peptide medicine is injected.
The tablet gets around that with 300 mg of sodium N-(8-[2-hydroxybenzoyl] amino) caprylate — SNAC, listed among the inactive ingredients as salcaprozate sodium. A 2024 review in Clinical Diabetes sets out three things it does at once (Solis-Herrera et al., Clin Diabetes 2024): it buffers the small pocket of gastric fluid around the dissolving tablet so pepsin cannot degrade the peptide; it keeps semaglutide monomeric rather than letting it clump; and it fluidises the membrane of the stomach lining so the molecule crosses directly.
Absorption happens in the stomach, only in the area immediately around the tablet as it dissolves. Once absorbed, the molecule behaves exactly as it does after injection, with a half-life of about a week (Granhall et al., Clin Pharmacokinet 2019) — see how semaglutide works.
Why oral semaglutide has such particular dosing rules
All three labels carry the same core instructions: empty stomach in the morning, up to 4 ounces (120 mL) of plain water, swallowed whole, then at least 30 minutes before food, other drinks or other oral medicines. None of it is a convenience. Each condition protects the narrow window the formulation depends on:
- Food and other drinks disperse the tablet and shift the local pH, so the concentrated pocket of SNAC never forms.
- Other oral medicines compete for the same absorption window, which matters for anyone on levothyroxine.
- Waiting less than 30 minutes cuts absorption of a dose that was already very small.
Even taken exactly as directed, the amount absorbed varies: day-to-day variability within one person runs 20–35% at steady state, and total variability including differences between people reaches up to 85%. A weekly injection has no equivalent daily-technique problem.
What the PIONEER trials measured
PIONEER 1 tested the tablet as monotherapy: 703 adults with type 2 diabetes managed by diet and exercise alone, randomised over 26 weeks to 3 mg, 7 mg, 14 mg or placebo. Under the treatment-policy estimand, placebo-adjusted treatment differences were −0.6%, −0.9% and −1.1% for HbA1c and −0.1 kg, −0.9 kg and −2.3 kg for body weight. Gastrointestinal events were most common, and 2.3–7.4% discontinued (Aroda et al., Diabetes Care 2019).
At the diabetes doses the weight effect is modest. The placebo-adjusted 2.3 kg treatment difference over 26 weeks at 14 mg is not the figure most people have in mind from the obesity trials of injectable semaglutide.
PIONEER 6 had already settled safety in 3,183 high-risk patients: major adverse cardiovascular events in 3.8% on oral semaglutide against 4.8% on placebo over a median 15.9 months, meeting the non-inferiority margin (Husain et al., NEJM 2019). Safety, though, is not benefit.
The 2025 cardiovascular addition
SOUL was built to test benefit: 9,650 participants with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease or both, randomised to once-daily oral semaglutide at a maximum of 14 mg or placebo, followed for a mean 47.5 months. A first major adverse cardiovascular event occurred in 12.0% of the semaglutide group against 13.8% on placebo (hazard ratio 0.86, 95% CI 0.77–0.96, P = 0.006). The confirmatory kidney composite did not separate (McGuire et al., NEJM 2025).
On 17 October 2025 the Food and Drug Administration added a cardiovascular indication to the 7 mg and 14 mg label: reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk, including those who have not had a prior event — the first oral GLP-1 to carry such an indication.
Three oral semaglutide brands, two different jobs
A higher-dose tablet for weight management arrived in December 2025 — oral semaglutide 25 mg. In OASIS 4, 205 participants on the 25 mg tablet lost a mean 13.6% of body weight by week 64 against 2.2% on placebo, with gastrointestinal adverse events in 74.0% versus 42.2% (Wharton et al., NEJM 2025).
| Rybelsus at 3 / 7 / 14 mg and Ozempic at 1.5 / 4 / 9 mg | Wegovy at 25 mg | |
|---|---|---|
| Indication | Type 2 diabetes; cardiovascular risk reduction in high-risk adults | Weight management; cardiovascular risk reduction with established cardiovascular disease |
| Escalation | Rybelsus: 3 mg for 30 days, then 7 mg, then 14 mg if needed; Ozempic: 1.5 mg for 30 days, then 4 mg, then 9 mg if needed | 1.5 mg, 4 mg, 9 mg, then 25 mg, at 30-day steps |
| Administration | Fasting, up to 4 oz plain water, 30-minute wait | Identical |
These branded products are distinct from compounded preparations and are dispensed as the manufacturers make them. Semaglutide brand names sorts out which name belongs to which product.
What Promise dispenses is none of these branded tablets. Its two GLP-1s are injectables prepared by a licensed U.S. compounding pharmacy — semaglutide with vitamin B12, and tirzepatide, a different molecule acting at two receptors rather than one. Weighing those is a choice between molecules, not routes.
Why the Promise formulation discussed here is injectable
FDA explains that drug compounding can produce sterile or nonsterile dosage forms, and its annual report gives solid oral dosage forms as an example. The compounded semaglutide guide describes the injectable formulation discussed here.
A tablet is a different proposition. The medicine is not the powder; it is the powder plus 300 mg of a permeation enhancer, pressed to an architecture that puts enhancer and peptide at the stomach lining together, in the right concentration, at the right moment. Change the form and you have changed the drug: the same active ingredient in a capsule, a lozenge or a sublingual drop is not the same medicine, because the delivery system was the hard part.
Preparations marketed as oral or sublingual semaglutide do circulate. What they lack is data: neither PIONEER nor OASIS studied drops or troches, and no published bioequivalence work compares them with the tablet. The FDA notes that compounded drugs are not reviewed for safety, effectiveness or quality before marketing, and flags salt forms such as semaglutide sodium and acetate as different active ingredients from the one in approved products (FDA, content current 15 June 2026).
Promise dispenses semaglutide as a compounded medication, which is different from an FDA-approved product: the formulation offered here — semaglutide with vitamin B12 — is not FDA-approved, and compounded medications are not reviewed by the FDA for safety, effectiveness, or quality. Regulatory status is one input into a prescribing decision rather than the whole of it, and a licensed provider may still prescribe a compounded formulation where they judge it appropriate — that decision is between you and your doctor.
What a prescriber weighs
Screening covers the same ground whatever the form: a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, which rules it out; previous pancreatitis; gallbladder disease; diabetic retinopathy; pregnancy or breastfeeding; and current medicines, since a GLP-1 alongside insulin or a sulfonylurea changes the hypoglycaemia picture.
For a tablet there is one further question, practical rather than clinical: whether a daily fasting routine is realistic. A tablet asks for thirty disciplined minutes every morning, and a dose swallowed with coffee is close to no dose at all.
A licensed provider in Promise's prescriber network reviews every request and prescribes only when it is appropriate for you. Not everyone qualifies, and being told no is a real outcome of a real review.